Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
PARIS and BRISBANE, California, June 3 /PRNewswire/ --
- Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY…